Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Th1Th17CM Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment.
Quirant-Sánchez B, Presas-Rodriguez S, Mansilla MJ, Teniente-Serra A, Hervás-García JV, Brieva L, Moral-Torres E, Cano A, Munteis E, Navarro-Barriuso J, Martínez-Cáceres EM, Ramo-Tello C. Quirant-Sánchez B, et al. Among authors: munteis e. Mediators Inflamm. 2019 Jun 26;2019:8147803. doi: 10.1155/2019/8147803. eCollection 2019. Mediators Inflamm. 2019. PMID: 31346315 Free PMC article.
[Multiple sclerosis epidemiological situation update: pertinence and set-up of a population based registry of new cases in Catalonia].
Otero S, Batlle J, Bonaventura I, Brieva L, Bufill E, Cano A, Carmona O, Escartín A, Marco M, Moral E, Munteis E, Nos C, Pericot I, Perkal H, Ramió-Torrentà L, Ramo-Tello C, Saiz A, Sastre-Garriga J, Tintoré M, Vaqué J, Montalban X; Grupo de Trabajo del Registro de Esclerosis Múltiple de Cataluña. Otero S, et al. Among authors: munteis e. Rev Neurol. 2010 May 16;50(10):623-33. Rev Neurol. 2010. PMID: 20473839 Free article. Spanish.
Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates.
Sepúlveda M, Aldea M, Escudero D, Llufriu S, Arrambide G, Otero-Romero S, Sastre-Garriga J, Romero-Pinel L, Martínez-Yélamos S, Sola-Valls N, Armangué T, Sotoca J, Escartín A, Robles-Cedeño R, Ramió-Torrentà L, Presas-Rodríguez S, Ramo-Tello C, Munteis E, Pelayo R, Gubieras L, Brieva L, Ortiz N, Hervás M, Mañé-Martínez MA, Cano A, Vela E, Tintoré M, Blanco Y, Montalban X, Graus F, Saiz A. Sepúlveda M, et al. Among authors: munteis e. Mult Scler. 2018 Dec;24(14):1843-1851. doi: 10.1177/1352458517735191. Epub 2017 Oct 6. Mult Scler. 2018. PMID: 28984163
Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients.
Quirant-Sánchez B, Hervás-García JV, Teniente-Serra A, Brieva L, Moral-Torres E, Cano A, Munteis E, Mansilla MJ, Presas-Rodriguez S, Navarro-Barriuso J, Ramo-Tello C, Martínez-Cáceres EM. Quirant-Sánchez B, et al. Among authors: munteis e. CNS Neurosci Ther. 2018 Dec;24(12):1175-1184. doi: 10.1111/cns.12851. Epub 2018 Apr 15. CNS Neurosci Ther. 2018. PMID: 29656444 Free PMC article.
Adaptive Features of Natural Killer Cells in Multiple Sclerosis.
Moreira A, Alari-Pahissa E, Munteis E, Vera A, Zabalza A, Llop M, Villarrubia N, Costa-García M, Álvarez-Lafuente R, Villar LM, López-Botet M, Martínez-Rodríguez JE. Moreira A, et al. Among authors: munteis e. Front Immunol. 2019 Oct 15;10:2403. doi: 10.3389/fimmu.2019.02403. eCollection 2019. Front Immunol. 2019. PMID: 31681293 Free PMC article. Clinical Trial.
48 results